Cover
Cover - shares | 9 Months Ended | |
Jun. 30, 2021 | Aug. 20, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Jun. 30, 2021 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2021 | |
Current Fiscal Year End Date | --09-30 | |
Entity File Number | 333-170315 | |
Entity Registrant Name | GlobeStar Therapeutics Corp | |
Entity Central Index Key | 0001502152 | |
Entity Tax Identification Number | 27-3480481 | |
Entity Incorporation, State or Country Code | WY | |
Entity Address, Address Line One | 719 Jadwin Avenue | |
Entity Address, City or Town | Richland | |
Entity Address, State or Province | WA | |
Entity Address, Postal Zip Code | 99352 | |
City Area Code | 206 | |
Local Phone Number | 451-1970 | |
Title of 12(b) Security | Common | |
Trading Symbol | GSTC | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 546,495,726 | |
Entity Information, Former Legal or Registered Name | Angiosoma Inc. |
CONSOLIDATED BALANCE SHEETS (Un
CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) | Jun. 30, 2021 | Sep. 30, 2020 |
CURRENT ASSETS | ||
Cash and cash equivalents | $ 20,476 | $ 81,442 |
Prepaid expenses | 4,783 | |
Inventory | 2,412 | |
Total current assets | 20,476 | 88,637 |
Fixed assets, net | 1,275 | |
TOTAL ASSETS | 20,476 | 89,912 |
Current Liabilities | ||
Accounts payable and accrued liabilities | 217,500 | 133,467 |
Accounts payable to related party | 57,155 | 173,568 |
Advances payable | 59,650 | 59,650 |
Current portion of convertible notes payable, net of discount of $3,287 and $34,923 respectively | 88,713 | 155,077 |
Current portion of accrued interest payable | 226,213 | 227,372 |
Total current liabilities | 649,231 | 749,134 |
TOTAL LIABILITIES | 649,231 | 749,134 |
STOCKHOLDERS’ DEFICIT | ||
Common stock, $0.001 par value, unlimited shares authorized; 476,832,632 and 436,218,342 shares issued and outstanding at June 30, 2021 and September 30, 2020, respectively | 476,832 | 436,217 |
Additional paid-in capital | 10,835,078 | 6,118,002 |
Stock payable, consisting of 25,980,000 and 0 shares to be issued at June 30, 2021 and September 30, 2020, respectively | 811,500 | |
Accumulated deficit | (12,754,062) | (7,215,338) |
TOTAL STOCKHOLDERS’ DEFICIT | (628,755) | (659,222) |
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | 20,476 | 89,912 |
Series A Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred stock; 20,000,000 shares authorized: | 0 | 0 |
TOTAL STOCKHOLDERS’ DEFICIT | ||
Series D Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred stock; 20,000,000 shares authorized: | 510 | 510 |
TOTAL STOCKHOLDERS’ DEFICIT | 510 | 510 |
Series E Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred stock; 20,000,000 shares authorized: | 1,000 | 1,000 |
TOTAL STOCKHOLDERS’ DEFICIT | 1,000 | 1,000 |
Series F Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred stock; 20,000,000 shares authorized: | 387 | 387 |
TOTAL STOCKHOLDERS’ DEFICIT | $ 387 | $ 387 |
CONSOLIDATED BALANCE SHEETS (_2
CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) | Jun. 30, 2021 | Sep. 30, 2020 |
Current portion of convertible notes payable, discount | $ 3,287 | $ 34,923 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, issued | 476,832,632 | 436,218,342 |
Common stock, outstanding | 476,832,632 | 436,218,342 |
Preferred stock, authorized | 20,000,000 | 20,000,000 |
Stock payable, shares | 25,980,000 | 0 |
Series A Preferred Stock [Member] | ||
Preferred stock, authorized | 6,000,000 | 6,000,000 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, issued | 0 | 0 |
Preferred stock, outstanding | 0 | 0 |
Series D Preferred Stock [Member] | ||
Preferred stock, authorized | 509,988 | 509,988 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, issued | 509,988 | 509,988 |
Preferred stock, outstanding | 509,988 | 509,988 |
Series E Preferred Stock [Member] | ||
Preferred stock, authorized | 1,000,000 | 1,000,000 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, issued | 1,000,000 | 1,000,000 |
Preferred stock, outstanding | 1,000,000 | 1,000,000 |
Series F Preferred Stock [Member] | ||
Preferred stock, authorized | 386,975 | 386,975 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, issued | 386,975 | 386,975 |
Preferred stock, outstanding | 386,975 | 386,975 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Income Statement [Abstract] | ||||
REVENUE | $ 77 | |||
Cost of goods sold | 2,412 | 14 | ||
Gross margin | (2,412) | 63 | ||
OPERATING EXPENSES | ||||
General and administrative expenses | 4,478,111 | 48,563 | 5,006,455 | 174,248 |
Total operating expenses | 4,478,111 | 48,563 | 5,006,455 | 174,248 |
LOSS FROM OPERATIONS | (4,478,111) | (48,563) | (5,008,867) | (174,185) |
OTHER INCOME (EXPENSE) | ||||
Loss on settlement of liabilities | (5,438) | (317,200) | ||
Interest expense | (34,949) | (39,422) | (212,657) | (193,149) |
Total other income (expense) | (40,387) | (39,422) | (529,857) | (193,149) |
Net loss | $ (4,518,498) | $ (87,985) | $ (5,538,724) | $ (367,334) |
Net loss per common share | $ (0.01) | $ 0 | $ (0.01) | $ 0 |
Weighted average shares outstanding - basic and diluted | 476,727,678 | 345,243,279 | 464,087,148 | 256,827,577 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Stock Payable [Member] | Retained Earnings [Member] | Series A Preferred Stock [Member] | Series D Preferred Stock [Member] | Series E Preferred Stock [Member] | Series F Preferred Stock [Member] | Total |
Beginning balance, value at Sep. 30, 2019 | $ 170,468 | $ 1,225,272 | $ (6,673,607) | $ 4,590,535 | $ 510 | $ 1,000 | $ 387 | $ (685,435) | |
Balance, Beginning (in shares) at Sep. 30, 2019 | 170,467,283 | 5,800,000 | 509,988 | 1,000,000 | 386,975 | ||||
Return of preferred shares and retirement of accrued compensation from legal settlement | 4,703,339 | $ (4,590,535) | 112,804 | ||||||
Common stock issued for conversion of convertible note payable and accrued interest | $ 39,833 | 44,967 | 84,800 | ||||||
Return of preferred shares and retirement of accrued compensation from legal settlement (in shares) | (5,800,000) | ||||||||
Common stock issued for conversion of convertible note payable and accrued interest (in shares) | 39,833,749 | ||||||||
Beneficial conversion discount on convertible notes payable | 32,000 | 32,000 | |||||||
Net loss | (161,037) | (161,037) | |||||||
Ending balance, value at Dec. 31, 2019 | $ 210,301 | 6,005,578 | (6,834,644) | $ 510 | $ 1,000 | $ 387 | (616,868) | ||
Balance, End (in shares) at Dec. 31, 2019 | 210,301,032 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Beginning balance, value at Sep. 30, 2019 | $ 170,468 | 1,225,272 | (6,673,607) | $ 4,590,535 | $ 510 | $ 1,000 | $ 387 | (685,435) | |
Balance, Beginning (in shares) at Sep. 30, 2019 | 170,467,283 | 5,800,000 | 509,988 | 1,000,000 | 386,975 | ||||
Stock-based compensation | |||||||||
Net loss | (367,334) | ||||||||
Ending balance, value at Jun. 30, 2020 | $ 383,120 | 6,034,819 | (7,040,941) | $ 510 | $ 1,000 | $ 387 | (621,105) | ||
Balance, End (in shares) at Jun. 30, 2020 | 383,120,160 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Beginning balance, value at Dec. 31, 2019 | $ 210,301 | 6,005,578 | (6,834,644) | $ 510 | $ 1,000 | $ 387 | (616,868) | ||
Balance, Beginning (in shares) at Dec. 31, 2019 | 210,301,032 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Common stock issued for conversion of convertible note payable and accrued interest | $ 93,977 | (24,017) | 69,960 | ||||||
Common stock issued for conversion of convertible note payable and accrued interest (in shares) | 93,977,186 | 0 | |||||||
Beneficial conversion discount on convertible notes payable | 60,000 | 60,000 | |||||||
Net loss | (118,312) | (118,312) | |||||||
Ending balance, value at Mar. 31, 2020 | $ 304,278 | 6,041,561 | (6,952,956) | $ 510 | $ 1,000 | $ 387 | (605,220) | ||
Balance, End (in shares) at Mar. 31, 2020 | 304,278,218 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Common stock issued for conversion of convertible note payable and accrued interest | $ 78,842 | (41,742) | 37,100 | ||||||
Common stock issued for conversion of convertible note payable and accrued interest (in shares) | 78,841,942 | 0 | |||||||
Beneficial conversion discount on convertible notes payable | 35,000 | 35,000 | |||||||
Net loss | (87,985) | (87,985) | |||||||
Ending balance, value at Jun. 30, 2020 | $ 383,120 | 6,034,819 | (7,040,941) | $ 510 | $ 1,000 | $ 387 | (621,105) | ||
Balance, End (in shares) at Jun. 30, 2020 | 383,120,160 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Beginning balance, value at Sep. 30, 2020 | $ 436,217 | 6,118,002 | (7,215,338) | $ 510 | $ 1,000 | $ 387 | (659,222) | ||
Balance, Beginning (in shares) at Sep. 30, 2020 | 436,218,342 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Common stock issued for conversion of convertible note payable and accrued interest | $ 19,269 | 45,391 | 64,660 | ||||||
Common stock issued for conversion of convertible note payable and accrued interest (in shares) | 19,269,286 | 0 | |||||||
Beneficial conversion discount on convertible notes payable | 30,000 | 30,000 | |||||||
Net loss | (124,395) | (124,395) | |||||||
Ending balance, value at Dec. 31, 2020 | $ 455,486 | 6,193,393 | (7,339,733) | $ 510 | $ 1,000 | $ 387 | (688,957) | ||
Balance, End (in shares) at Dec. 31, 2020 | 455,487,628 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Beginning balance, value at Sep. 30, 2020 | $ 436,217 | 6,118,002 | (7,215,338) | $ 510 | $ 1,000 | $ 387 | (659,222) | ||
Balance, Beginning (in shares) at Sep. 30, 2020 | 436,218,342 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Stock-based compensation | 4,534,179 | ||||||||
Net loss | (5,538,724) | ||||||||
Ending balance, value at Jun. 30, 2021 | $ 476,832 | 10,835,078 | 811,500 | (12,754,062) | $ 510 | $ 1,000 | $ 387 | (628,755) | |
Balance, End (in shares) at Jun. 30, 2021 | 476,832,632 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Beginning balance, value at Dec. 31, 2020 | $ 455,486 | 6,193,393 | (7,339,733) | $ 510 | $ 1,000 | $ 387 | (688,957) | ||
Balance, Beginning (in shares) at Dec. 31, 2020 | 455,487,628 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Issuance of common stock and retirement of accrued compensation with former officer | $ 2,600 | 132,600 | 312,000 | 447,200 | |||||
Issuance of common stock and retirement of accrued compensation with former officer (in shares) | 2,600,000 | ||||||||
Common stock issued for conversion of convertible note payable and accrued interest | $ 17,552 | 97,990 | 115,542 | ||||||
Common stock issued for conversion of convertible note payable and accrued interest (in shares) | 17,551,147 | 0 | |||||||
Sale of common stock units for cash proceeds | 499,500 | 499,500 | |||||||
Repurchase of preferred stock from former officer | (324,000) | $ (1,000) | (325,000) | ||||||
Repurchase of preferred stock from former officer (in shares) | (1,000,000) | ||||||||
Issuance of preferred stock to officer | 324,000 | $ 1,000 | 325,000 | ||||||
Issuance of preferred stock to officer (in shares) | 1,000,000 | ||||||||
Settlement of accounts payable with related party | 38,130 | 38,130 | |||||||
Beneficial conversion discount on convertible notes payable | 100,000 | 100,000 | |||||||
Net loss | (895,831) | (895,831) | |||||||
Ending balance, value at Mar. 31, 2021 | $ 475,638 | 6,562,113 | 811,500 | (8,235,564) | $ 510 | $ 1,000 | $ 387 | (384,416) | |
Balance, End (in shares) at Mar. 31, 2021 | 475,638,775 | 0 | 509,988 | 1,000,000 | 386,975 | ||||
Stock Issued During Period, Value, New Issues | 499,500 | 499,500 | |||||||
Common stock issued for conversion of convertible note payable and accrued interest | $ 1,194 | 33,786 | 34,980 | ||||||
Common stock issued for conversion of convertible note payable and accrued interest (in shares) | 1,193,857 | 0 | |||||||
Beneficial conversion discount on convertible notes payable | 30,000 | 30,000 | |||||||
Stock-based compensation | 4,209,179 | 4,209,179 | |||||||
Net loss | (4,518,498) | (4,518,498) | |||||||
Ending balance, value at Jun. 30, 2021 | $ 476,832 | $ 10,835,078 | $ 811,500 | $ (12,754,062) | $ 510 | $ 1,000 | $ 387 | $ (628,755) | |
Balance, End (in shares) at Jun. 30, 2021 | 476,832,632 | 0 | 509,988 | 1,000,000 | 386,975 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) | 9 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
CASH FLOW FROM OPERATING ACTIVITIES: | ||
Net loss | $ (5,538,724) | $ (367,334) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock compensation | 4,534,179 | |
Depreciation | 1,275 | 1,169 |
Amortization of discount on convertible note payable | 201,636 | 185,395 |
Loss on conversion of notes payable | ||
Loss on settlement of liabilities | 317,200 | |
Changes in operating assets and liabilities | ||
Inventory | 2,412 | 34 |
Prepaid expenses | 4,783 | (778) |
Accounts payable and accrued liabilities | 84,035 | (1,598) |
Accounts payable and accrued liabilities to related party | 51,717 | 5,000 |
Accrued interest payable | 11,021 | 7,754 |
NET CASH (USED IN) OPERATING ACTIVITIES | (330,466) | (170,358) |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Cash used to acquire fixed assets | (1,782) | |
NET CASH (USED IN) INVESTING ACTIVITIES | (1,782) | |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Proceeds from sale of common stock units | 499,500 | |
Repurchase of preferred stock from former officer | (325,000) | |
Proceeds from convertible notes payable, net | 95,000 | 122,000 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 269,500 | 122,000 |
NET CHANGE IN CASH AND CASH EQUIVALENTS | (60,966) | (50,140) |
Cash and cash equivalents at beginning of period | 81,442 | 100,459 |
Cash and cash equivalents at end of period | 20,476 | 50,319 |
Cash paid during the period for: | ||
Interest | ||
Taxes | ||
Noncash investing and financing transactions: | ||
Conversion of convertible notes payable and accrued interest into common stock | 215,180 | 191,860 |
Beneficial conversion discount on convertible notes payable | 160,000 | 127,000 |
Common shares issued to settle liabilities with former officer | 130,000 | |
Settlement of liabilities with related party | 38,130 | |
Return of Series A preferred shares and settlement of related party compensation | $ 4,703,339 |
General Organization and Busine
General Organization and Business | 9 Months Ended |
Jun. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
General Organization and Business | Note 1. General Organization and Business GlobeStar Therapeutics Corporation (the “Company”) was incorporated on April 29, 2016. The Company’s year-end is September 30. On October 4, 2019, the Company filed Articles of Continuance with the Secretary of State of Wyoming to continue its business in the state of Wyoming. As part of these Articles of Continuance, effective October 4, 2019, the Company has no limit on the authorized shares of common stock that can be issued. The Company filed its Certificate of Dissolution with the Secretary of State of Nevada on October 21, 2019 because it is no longer a Nevada corporation. The Company changed its name to GlobeStar Therapeutics Corporation on April 27, 2021 from Angiosoma Inc. to better reflect our expanded platform of products that include breakthrough addition of treatment for Multiple Sclerosis and other neurodegenerative diseases. The potential pharmaceutical products related to treatment for multiple sclerosis are licensed to the Company through the worldwide licensing agreement described in Note 7. On April 27, 2021, the Board of Directors elected Brooke Greenwald as Chief Marketing Officer and a director of the Company. On April 27, 2021, the Board of Directors of the Company elected Steven F. Penderghast as a director of the Company. On April 28, 2021, the Board of Directors elected William Farley as a director of the Company. On May 6, 2021, the Board of Directors of the Company elected David Croom as Executive Vice President of the Company. |
Going Concern and Summary of Si
Going Concern and Summary of Significant Accounting Policies | 9 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Going Concern and Summary of Significant Accounting Policies | Note 2. Going Concern and Summary of Significant Accounting Policies The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended June 30, 2021, the Company had a net loss of $ 5,755,065 345,466 628,755 These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Management has plans to address the Company’s financial situation as follows: In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company’s ability to continue as a going concern. In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations. Interim Financial Statements The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X and should be read in conjunction with the audited financial statements and notes thereto for the year ended September 30, 2020 which are included on our Form 10-K filed on December 3, 2020. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the three and nine months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full fiscal year ending September 30, 2021. Consolidated Financial Statements The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation. Recently Issued Accounting Pronouncements We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. |
Convertible Notes Payable
Convertible Notes Payable | 9 Months Ended |
Jun. 30, 2021 | |
Debt Disclosure [Abstract] | |
Convertible Notes Payable | Note 3. Convertible Notes Payable Convertible notes payable consisted of the following at June 30, 2021 and September 30, 2020: June 30, 2021 September 30, 2020 Convertible note dated April 13, 2017 20,000 3 0.01 $ 20,000 $ 20,000 Convertible note dated March 30, 2020 28,000 January 15, 2021 12 convertible beginning September 26, 2020 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 1,680 9,275,000 — 28,000 Convertible note dated June 10, 2020 33,000 April 15, 2021 12 convertible beginning December 8, 2020 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 1,980 9,994,286 — 33,000 Convertible note dated July 7, 2020 38,000 May 15, 2021 12 convertible beginning January 3, 2020 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 2,280 10,886,486 — 38,000 Convertible note dated July 30, 2020 33,000 June 15 2021 12 convertible beginning February 20, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 1,980 4,115,294 — 33,000 Convertible note dated August 24, 2020 38,000 June 30, 2021 12 convertible beginning January 26, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 2,280 2,549,367 — 38,000 Convertible note dated October 6, 2020 33,000 July 30 2021 12 convertible beginning April 4, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 1,980 1,193,857 — — Convertible note dated January 5, 2021 38,500 January 5, 2022 12 convertible beginning July 4, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 38,500 — Convertible note dated February 4, 2021 33,500 February 4, 2022 12 convertible beginning August 3, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 33,500 — Total current convertible notes payable 92,000 190,000 Less: discount on convertible notes payable (3,287 ) (34,923 ) Total convertible notes payable, net of discount $ 88,713 $ 155,077 All principal along with accrued interest is payable on the maturity date. The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.99% of the outstanding stock of the Company. During the three months ended December 31, 2020, the Company recognized $ 3,000 30,000 7,000 100,000 7,000 30,000 During the three and nine months ended June 30, 2021, the Company recognized interest expense on convertible notes of $ 2,225 10,931 32,452 201,636 7,754 17,561 39,887 185,395 As of June 30, 2021 and September 30, 2020, accrued interest was $ 226,123 227,372 Advances As of June 30, 2021 and September 30, 2020, the Company had non-interest bearing advances payable to third parties of $ 59,650 |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Jun. 30, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 4. Related Party Transactions In January 2021, the Company’s former Chief Executive Officer Sydney Jim agreed to forgive all accrued but unpaid compensation of $ 38,130 In March 2021, the Company entered into severance agreement with its former CEO Alex Blankenship. The Company owed Ms. Blankenship unpaid compensation of $ 130,000 8,600,000 447,200 317,200 2,600,000 1,000,000 325,000 325,000 David Summers, a significant shareholder of the Company, formerly provided consulting services to the Company related to the development of our products. In addition, the Company had previously rented office space from Mr. Summers for $ 400 112,804 5,800,000 4,590,535 |
Stockholders_ Equity (Deficit)
Stockholders’ Equity (Deficit) | 9 Months Ended |
Jun. 30, 2021 | |
Equity [Abstract] | |
Stockholders’ Equity (Deficit) | Note 5. Stockholders’ Equity (Deficit) Preferred Series A During the three months ended December 31, 2019, the Company entered into a settlement agreement with David Summers, the Company’s former CEO and a common stockholder. As part of this settlement, David Summers returned 5,800,000 Preferred Series E On March 31, 2021, The Company agreed to repurchase 1,000,000 325,000 325,000 Common Stock Units During the three months ended March 31, 2021, the Company sold common stock units to investors. Each unit consist of 400,000 600,000 0.03 499,500 29,970,000 350,462 261.3 261.8 0 0.19 0.24 Common stock issued for conversion of convertible notes payable During the three months ended December 31, 2020, the Company issued 19,269,286 61,00 3,660 During the three months ended March 31, 2021, the Company issued 17,551,147 109,000 6,540 During the three months ended June 30, 2021, the Company issued 1,193,857 30,000 1,980 During the three months ended December 31, 2019, the Company issued 39,833,749 80,000 4,800 During the three months ended March 31, 2020, the Company issued 93,977,186 66,000 3,960 During the three months ended June 30, 2020, the Company issued 78,841,942 35,000 2,100 Common Stock Options During the three months ended June 30, 2021, the Board of Directors approved grants of 70,000,000 0.003 two two years 1 2 years 253.3 262.8 0 0.35 0.36 The following table summarizes the stock option activity for the nine months ended June 30, 2021: Schedule of Stock Option Activity Options Weighted- Average Exercise Price Per Share Outstanding, December 31, 2020 — $ — Granted 70,000,000 $ 0.003 Exercised — $ — Forfeited — $ — Expired — $ — Outstanding, June 30, 2021 70,000,000 $ 0.003 As of June 30, 2021, the aggregate intrinsic value of options vested and outstanding were $ 1,925,000 1.86 years Beneficial conversion feature During the nine months ended June 30, 2021, the Company charged to additional paid-in capital the aggregate amount of $ 160,000 |
Commitments and Contingent Liab
Commitments and Contingent Liabilities | 9 Months Ended |
Jun. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingent Liabilities | Note 6. Commitments and Contingent Liabilities Litigation The Company was involved in a legal dispute with Mr. David Summers, a significant shareholder, regarding the settlement of claims on certain patents and formulas. In October 2019, the Company entered into a settlement agreement with David Summers whereby all claims, disputes and litigation were dismissed. Mr. Summers returned 5,800,000 112,804 |
License Agreement
License Agreement | 9 Months Ended |
Jun. 30, 2021 | |
License Agreement | |
License Agreement | Note 7. License Agreement Effective August 23, 2020 the Company’s wholly-owned subsidiary, SomaCeuticals, Inc. entered into an exclusive global license agreement with 7 to Stand, Inc. for the rights to U.S. patent 10,610,592 7.1 ● Common shares representing 5% of total number of outstanding common shares of the Company immediately following any change of control of the Company; the Company will issue 29,130,167 shares of common stock as a result of the change of control discussed in Note 5. These shares were issued in July 2021. ● 29,130,167 Common shares immediately following the first round of funding under a private offer of equity or debt securities; These shares were issued in July 2021. ● 29,130,167 Common shares immediately following the commencement of clinical trials for Federal Drug Administration clearance of the product; and ● Common shares representing an adjustment to increase 7 to Stand’s total ownership to 19.99% of total number of outstanding common shares of the Company immediately following FDA clearance of the product for sale. The Company expects to issue 29,130,166 shares of common stock related to this provision if met. ● No royalties have been earned or paid to 7 to Stand. The license agreement may be terminated by 7 to Stand if 1) SomaCeuticals does not begin clinical trials within one year of the agreement; 2) if SomaCeuticals terminates the continuation of the clinical trials; or 3) shall not commence marketing the product within reasonable time after obtaining FDA approval. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Jun. 30, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 8. Subsequent Events Subsequent to June 30, 2021, the Company issued a total of 2,802,760 72,000 4,320 In July 2021, the Company issued 8,600,000 In July 2021, the Company issued 58,260,334 |
Going Concern and Summary of _2
Going Concern and Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Interim Financial Statements | Interim Financial Statements The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X and should be read in conjunction with the audited financial statements and notes thereto for the year ended September 30, 2020 which are included on our Form 10-K filed on December 3, 2020. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the three and nine months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full fiscal year ending September 30, 2021. |
Consolidated Financial Statements | Consolidated Financial Statements The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, SomaCeuticals, Inc., First Titan Energy, LLC and First Titan Technical, LLC from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. |
Convertible Notes Payable (Tabl
Convertible Notes Payable (Tables) | 9 Months Ended |
Jun. 30, 2021 | |
Debt Disclosure [Abstract] | |
Convertible notes payable consisted of the following at June 30, 2021 and September 30, 2020: | Convertible notes payable consisted of the following at June 30, 2021 and September 30, 2020: June 30, 2021 September 30, 2020 Convertible note dated April 13, 2017 20,000 3 0.01 $ 20,000 $ 20,000 Convertible note dated March 30, 2020 28,000 January 15, 2021 12 convertible beginning September 26, 2020 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 1,680 9,275,000 — 28,000 Convertible note dated June 10, 2020 33,000 April 15, 2021 12 convertible beginning December 8, 2020 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 1,980 9,994,286 — 33,000 Convertible note dated July 7, 2020 38,000 May 15, 2021 12 convertible beginning January 3, 2020 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 2,280 10,886,486 — 38,000 Convertible note dated July 30, 2020 33,000 June 15 2021 12 convertible beginning February 20, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 1,980 4,115,294 — 33,000 Convertible note dated August 24, 2020 38,000 June 30, 2021 12 convertible beginning January 26, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 2,280 2,549,367 — 38,000 Convertible note dated October 6, 2020 33,000 July 30 2021 12 convertible beginning April 4, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 1,980 1,193,857 — — Convertible note dated January 5, 2021 38,500 January 5, 2022 12 convertible beginning July 4, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 38,500 — Convertible note dated February 4, 2021 33,500 February 4, 2022 12 convertible beginning August 3, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. 33,500 — Total current convertible notes payable 92,000 190,000 Less: discount on convertible notes payable (3,287 ) (34,923 ) Total convertible notes payable, net of discount $ 88,713 $ 155,077 |
Stockholders_ Equity (Deficit)
Stockholders’ Equity (Deficit) (Tables) | 9 Months Ended |
Jun. 30, 2021 | |
Equity [Abstract] | |
The following table summarizes the stock option activity for the nine months ended June 30, 2021: | The following table summarizes the stock option activity for the nine months ended June 30, 2021: Schedule of Stock Option Activity Options Weighted- Average Exercise Price Per Share Outstanding, December 31, 2020 — $ — Granted 70,000,000 $ 0.003 Exercised — $ — Forfeited — $ — Expired — $ — Outstanding, June 30, 2021 70,000,000 $ 0.003 |
Going Concern and Summary of _3
Going Concern and Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||||||
Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Jun. 30, 2021 | Jun. 30, 2020 | |
Accounting Policies [Abstract] | ||||||||
Net loss | $ (4,518,498) | $ (895,831) | $ (124,395) | $ (87,985) | $ (118,312) | $ (161,037) | $ (5,538,724) | $ (367,334) |
Cash flow from operating activities | (330,466) | $ (170,358) | ||||||
Working capital | $ 628,755 | $ 628,755 |
Convertible notes payable consi
Convertible notes payable consisted of the following at June 30, 2021 and September 30, 2020: (Details) - USD ($) | 9 Months Ended | |
Jun. 30, 2021 | Sep. 30, 2020 | |
Short-term Debt [Line Items] | ||
Total current convertible notes payable | $ 92,000 | $ 190,000 |
Less: discount on convertible notes payable | (3,287) | (34,923) |
Long-term convertible notes payable, net of discount | $ 88,713 | 155,077 |
Convertible Note Date April 13 2017 [Member] | ||
Short-term Debt [Line Items] | ||
Dated | Apr. 13, 2017 | |
Amount | $ 20,000 | |
Interest | 3.00% | |
Convertible rate | $ 0.01 | |
Convertible note | $ 20,000 | 20,000 |
Convertible Note Dated March 30 2020 [Member] | ||
Short-term Debt [Line Items] | ||
Dated | Mar. 30, 2020 | |
Amount | $ 28,000 | |
Interest | 12.00% | |
Convertible note | $ 0 | 28,000 |
Maturing | January 15, 2021 | |
Convertible | convertible beginning September 26, 2020 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. | |
Amount converted | $ 1,680 | |
Converted shares of common stock | 9,275,000 | |
Convertible Note Dated June 10 2020 [Member] | ||
Short-term Debt [Line Items] | ||
Dated | Jun. 10, 2020 | |
Amount | $ 33,000 | |
Interest | 12.00% | |
Convertible note | $ 0 | 33,000 |
Maturing | April 15, 2021 | |
Convertible | convertible beginning December 8, 2020 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. | |
Amount converted | $ 1,980 | |
Converted shares of common stock | 9,994,286 | |
Convertible Note Dated July 7 2020 [Member] | ||
Short-term Debt [Line Items] | ||
Dated | Jul. 7, 2020 | |
Amount | $ 38,000 | |
Interest | 12.00% | |
Convertible note | $ 0 | 38,000 |
Maturing | May 15, 2021 | |
Convertible | convertible beginning January 3, 2020 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. | |
Amount converted | $ 2,280 | |
Converted shares of common stock | 10,886,486 | |
Convertible Note Dated July 30 2020 [Member] | ||
Short-term Debt [Line Items] | ||
Dated | Jul. 30, 2020 | |
Amount | $ 33,000 | |
Interest | 12.00% | |
Convertible note | $ 0 | 33,000 |
Maturing | June 15 2021 | |
Convertible | convertible beginning February 20, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. | |
Amount converted | $ 1,980 | |
Converted shares of common stock | 4,115,294 | |
Convertible Note Dated August 24 2020 [Member] | ||
Short-term Debt [Line Items] | ||
Dated | Aug. 24, 2020 | |
Amount | $ 38,000 | |
Interest | 12.00% | |
Convertible note | $ 0 | 38,000 |
Maturing | June 30, 2021 | |
Convertible | convertible beginning January 26, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. | |
Amount converted | $ 2,280 | |
Converted shares of common stock | 2,549,367 | |
Convertible Note Dated October 6 2020 [Member] | ||
Short-term Debt [Line Items] | ||
Dated | Oct. 6, 2020 | |
Amount | $ 33,000 | |
Interest | 12.00% | |
Convertible note | $ 0 | 0 |
Maturing | July 30 2021 | |
Convertible | convertible beginning April 4, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. | |
Amount converted | $ 1,980 | |
Converted shares of common stock | 1,193,857 | |
Convertible Note Dated January 5 2021 [Member] | ||
Short-term Debt [Line Items] | ||
Dated | Jan. 5, 2021 | |
Amount | $ 38,500 | |
Interest | 12.00% | |
Convertible note | $ 38,500 | 0 |
Maturing | January 5, 2022 | |
Convertible | convertible beginning July 4, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. | |
Convertible Note Dated February 4 2021 [Member] | ||
Short-term Debt [Line Items] | ||
Dated | Feb. 4, 2021 | |
Amount | $ 33,500 | |
Interest | 12.00% | |
Convertible note | $ 33,500 | $ 0 |
Maturing | February 4, 2022 | |
Convertible | convertible beginning August 3, 2021 into common stock at a rate of 65% of the average of the two lowest bid prices during the 15 trading days prior to conversion. |
Convertible Notes Payable (Deta
Convertible Notes Payable (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | |||||
Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Sep. 30, 2020 | |
Short-term Debt [Line Items] | |||||||
Beneficial conversion discount on convertible note payable | $ 160,000 | $ 127,000 | |||||
Interest Expense | $ 34,949 | $ 39,422 | 212,657 | 193,149 | |||
Current portion of accrued interest payable | 226,213 | 226,213 | $ 227,372 | ||||
Short-term Debt | 59,650 | $ 59,650 | $ 59,650 | ||||
Convertible Debt [Member] | |||||||
Short-term Debt [Line Items] | |||||||
Debt Instrument, Convertible, Terms of Conversion Feature | The notes are convertible into common stock at the option of the holder. The holder of the notes cannot convert the notes into shares of common stock if that conversion would result in the holder owning more than 4.99% of the outstanding stock of the Company. | ||||||
Deferred finance costs | 7,000 | $ 7,000 | $ 3,000 | $ 7,000 | |||
Beneficial conversion discount on convertible note payable | 30,000 | $ 100,000 | $ 30,000 | ||||
Interest Expense | 2,225 | 7,754 | 10,931 | 17,561 | |||
Amortization of Debt Discount (Premium) | $ 32,452 | $ 39,887 | $ 201,636 | $ 185,395 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2021 | Jun. 30, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Jan. 31, 2021 | |
Related Party Transaction [Line Items] | |||||
Issuance of common stock | $ 499,500 | ||||
Fair value of stock | $ 1,925,000 | 1,925,000 | |||
Share based compensation | 4,209,179 | 4,534,179 | |||
Unpaid liability | 112,804 | $ 112,804 | |||
Series E Preferred Stock [Member] | |||||
Related Party Transaction [Line Items] | |||||
Share based compensation | |||||
Series A Preferred Stock [Member] | |||||
Related Party Transaction [Line Items] | |||||
Share based compensation | |||||
Chief Executive Officer [Member] | |||||
Related Party Transaction [Line Items] | |||||
Settlement of liabilities | $ 38,130 | ||||
Unpaid compensation | $ 130,000 | ||||
Issuance of common stock | 8,600,000 | ||||
Fair value of stock | 447,200 | ||||
Loss on settlement | $ 317,200 | ||||
Share issued | 2,600,000 | ||||
Chief Executive Officer [Member] | Series E Preferred Stock [Member] | |||||
Related Party Transaction [Line Items] | |||||
Purchase price of stock | 1,000,000 | 1,000,000 | |||
Share based compensation | $ 325,000 | ||||
Chief Executive Officer [Member] | Series A Preferred Stock [Member] | |||||
Related Party Transaction [Line Items] | |||||
Number of shares cancelled | 5,800,000 | ||||
Book Value | $ 4,590,535 | ||||
New CEO [Member] | Series E Preferred Stock [Member] | |||||
Related Party Transaction [Line Items] | |||||
Share based compensation | $ 325,000 | 325,000 | |||
Majority Shareholder [Member] | |||||
Related Party Transaction [Line Items] | |||||
Operating Leases, Rent Expense, Minimum Rentals | $ 400 |
The following table summarizes
The following table summarizes the stock option activity for the nine months ended June 30, 2021: (Details) | 9 Months Ended |
Jun. 30, 2021$ / sharesshares | |
Equity [Abstract] | |
Outstanding at beginning | shares | |
Outstanding at beginning | $ 0 |
Granted | shares | 70,000,000 |
Granted | $ 0.003 |
Expired | shares | 0 |
Exercised | $ 0 |
Forfeited | shares | 0 |
Forfeited | $ 0 |
Expired | $ 0 |
Outstanding at ending | shares | 70,000,000 |
Options exercisable at ending | $ 0.003 |
Stockholders_ Equity (Deficit_2
Stockholders’ Equity (Deficit) (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||
Mar. 31, 2021 | Oct. 31, 2019 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Jun. 30, 2021 | Jun. 30, 2020 | Sep. 30, 2020 | |
Class of Stock [Line Items] | |||||||||||
Share based compensation | $ 4,209,179 | $ 4,534,179 | |||||||||
Proceeds from sale of common stock units | $ 499,500 | ||||||||||
Dividend yield | 0.00% | ||||||||||
Options granted | 476,832,632 | 476,832,632 | 436,218,342 | ||||||||
Aggregate instrinsic value | $ 1,925,000 | $ 1,925,000 | |||||||||
Expected remaining life | 1 year 10 months 10 days | ||||||||||
Amount of beneficial conversion feature | $ 160,000 | 127,000 | |||||||||
Minimum [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Expected term (in years) | 1 year | ||||||||||
Volatility | 253.30% | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 0.35% | ||||||||||
Maximum [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Expected term (in years) | 2 years | ||||||||||
Volatility | 262.80% | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 0.36% | ||||||||||
Board Of Directors [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Options granted | 70,000,000 | 70,000,000 | |||||||||
Excercise price of option | $ 0.003 | $ 0.003 | |||||||||
Vesting period | 2 years | ||||||||||
Common Stock [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Share based compensation | |||||||||||
Common Stock, Shares Authorized | 400,000 | 400,000 | |||||||||
Proceeds from sale of common stock units | $ 499,500 | ||||||||||
Common stock issued for conversion of convertible note payable | 1,193,857 | 17,551,147 | 19,269,286 | 78,841,942 | 93,977,186 | 39,833,749 | |||||
Fair value of warrants | $ 350,462 | ||||||||||
Volatility ranging of minimum price | 261.30% | ||||||||||
Volatility ranging of maximum price | 261.80% | ||||||||||
Dividend yield | 0.00% | ||||||||||
Risk free range minimum price | 0.19% | ||||||||||
Risk free range maximum price | 0.24% | ||||||||||
Common Stock [Member] | Convertible Note Payable [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Common stock issued for conversion of convertible note payable | 1,193,857 | 17,551,147 | 19,269,286 | 78,841,942 | 93,977,186 | 39,833,749 | |||||
Face amount | $ 109,000 | $ 30,000 | $ 109,000 | $ 61 | $ 35,000 | $ 66,000 | $ 80,000 | $ 30,000 | $ 35,000 | ||
Debt accrued interest | 1,980 | $ 6,540 | $ 3,660 | $ 2,100 | $ 3,960 | $ 4,800 | |||||
Warrant [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Purchase price of stock | 600,000 | ||||||||||
Warrrant excercise pice | $ 0.03 | ||||||||||
Common stock issued for conversion of convertible note payable | 29,970,000 | ||||||||||
Chief Executive Officer [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Proceeds from sale of common stock units | 8,600,000 | ||||||||||
Aggregate instrinsic value | $ 447,200 | $ 447,200 | |||||||||
Series A Preferred Stock [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Share based compensation | |||||||||||
Common stock issued for conversion of convertible note payable | 0 | 0 | 0 | 0 | 0 | ||||||
Series A Preferred Stock [Member] | David Summers [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Number of shares cancelled | 5,800,000 | 5,800,000 | |||||||||
Series A Preferred Stock [Member] | Chief Executive Officer [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Number of shares cancelled | 5,800,000 | ||||||||||
Series E Preferred Stock [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Share based compensation | |||||||||||
Series E Preferred Stock [Member] | Chief Executive Officer [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Purchase price of stock | 1,000,000 | 1,000,000 | |||||||||
Cash | $ 325,000 | $ 325,000 | |||||||||
Share based compensation | $ 325,000 | ||||||||||
Series E Preferred Stock [Member] | New CEO [Member] | |||||||||||
Class of Stock [Line Items] | |||||||||||
Share based compensation | $ 325,000 | $ 325,000 |
Commitments and Contingent Li_2
Commitments and Contingent Liabilities (Details Narrative) - David Summers [Member] - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended |
Oct. 31, 2019 | Dec. 31, 2019 | Jun. 30, 2021 | |
Affiliate, Collateralized Security [Line Items] | |||
Liability for compensation amounts | $ 112,804 | ||
Series A Preferred Stock [Member] | |||
Affiliate, Collateralized Security [Line Items] | |||
Number of shares cancelled | 5,800,000 | 5,800,000 |
License Agreement (Details Narr
License Agreement (Details Narrative) - License Agreement [Member] - Patents [Member] | Aug. 23, 2020shares |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Royalty of net sales | 7.10% |
Fabrizio De Silvestri [Member] | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Rights to issued | 10,610,592 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - Common Stock [Member] - USD ($) | 1 Months Ended | 9 Months Ended |
Jul. 31, 2021 | Jun. 30, 2021 | |
Subsequent Event [Line Items] | ||
Converted shares of common stock | 2,802,760 | |
Face amount | $ 72,000 | |
Outstanding convertible debt | $ 4,320 | |
Subsequent Event [Member] | ||
Subsequent Event [Line Items] | ||
Number of shares issued | 58,260,334 | |
Chief Executive Officer [Member] | Subsequent Event [Member] | ||
Subsequent Event [Line Items] | ||
Number of shares issued | 8,600,000 |